Chiusura precedente | 1,9940 |
Aperto | 0,0000 |
Denaro | 0,0000 x 0 |
Lettera | 0,0000 x 0 |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 5.479 |
Capitalizzazione | 763.821 |
Beta (5 anni mensile) | 1,05 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,3040 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development strategy based on two platforms: the late-stage masitinib platform and the new microtubule platform Masitinib platform: License search for masitinibStudies in amyotrophic lateral sclerosis (ALS), mastocytosis, MCAS and Covid-19 are ongoingOngoing EMA and Health Canada procedures for conditional authorisation of masitinib in ALSTimetable extension granted by
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE EUROPEAN MEDICINES AGENCY'S TIMETABLE FOR EXAMINATION OF THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS BASED ON THE UPDATED TIMETABLE, A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS EXPECTED DURING THE FIRST QUARTER OF 2024 Paris, 18 September, 2023, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today provided an update on the European Medicines Agency’s (EMA) Committee for Medicinal Products for
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER (mCRPC), STRENGTHENING THE COMPANY’S INTELLECTUAL PROPERTY POSITION UNTIL 2042 Paris, 26 June, 2023, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a patent relating to methods of treating (mCRPC) with its lead compound masitinib, based on findings